RT @NicoleKuderer: Important study re autoantibodies (A-AB) after CTL4-A inh (Ipilimumab): This is still a small study (not stats power for…
RT @CIR_AACR: Ipilimumab treatment of patients with melanoma can induce autoantibodies, resulting in more immune-related adverse events but…
RT @CIR_AACR: Ipilimumab treatment of patients with melanoma can induce autoantibodies, resulting in more immune-related adverse events but…
Ipilimumab treatment of patients with melanoma can induce autoantibodies, resulting in more immune-related adverse events but also a survival and response benefit #Ipilimumab #Autoantibodies #ImmuneAdverseEvents https://t.co/TTAx7I892p https://t.co/Z5VLaO8
RT @NicoleKuderer: Important study re autoantibodies (A-AB) after CTL4-A inh (Ipilimumab): This is still a small study (not stats power for…
Important study re autoantibodies (A-AB) after CTL4-A inh (Ipilimumab): This is still a small study (not stats power for proof most correlations) but hinting at: most pts who develop A-AB on Ipi develop some form of organ inflammation. Are these transient?
RT @hotirishmonkey: A nice study demonstrating an association between autoantibodies and both adverse events and efficacy during IC therapy…
RT @LCalabreseDO: Pre-screening for AutoAbs has minimal predictive power for most irAEs- this needs to be verified ! @CCalabreseDO @cappeli…
Pre-screening for AutoAbs has minimal predictive power for most irAEs- this needs to be verified ! @CCalabreseDO @cappeliMD Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors https://t.co/yu95XV9alz
A nice study demonstrating an association between autoantibodies and both adverse events and efficacy during IC therapy. As ~20% of normal people have circulating autoantibodies, it would be fascinating to see if the respond better to IC therapy. https://t
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors https://t.co/4FlPoOvnzl
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
RT @Aiims1742: Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. T…
Important paper in @AACR Cancer Immunology Research: 20% of patients receiving ipilimumab develop de novo autoantibodies. Those who do are at risk for developing autoantibodies (especially anti-thyroid) on subsequent aPD-1 regimens. https://t.co/CX3sYeX3b
#Autoantibody development under treatment with immune checkpoint inhibitor ipilimumab https://t.co/jk4X3gyrGU
Autoantibody development under treatment with immune checkpoint inhibitors https://t.co/tSdy1Kp388